title: Role of antibody synthesis and complement activation in concordant xenograft retransplantation.
abstract: A mouse-to-rat heart retransplantation model was used to study the effects of complement depletion and antibody production with regard to graft survival and anti-donor antibody specificity. Retransplantation was performed 3 weeks after the first transplantation in the presence of absence of 15-deoxyspergualin (DSG) immunosuppression. Untreated animals rejected their first graft after 3 days and retransplantation resulted in a hyperacute rejection within 2 min. A low titer of preformed anti-mouse lymphocytotoxic antibodies of the IgM subclass was found in serum collected from the unoperated rat. The rejection gave rise to a synthesis of IgG antidonor antibodies reacting with both graft endothelium and sarcolemma. Immunofluorescent staining of the rejected first heart graft showed moderate IgM and IgG antibody deposits on the graft vascular endothelium, while only IgG was found in the second graft. There was no C3 deposition found in the first mouse graft, as was the case in the second mouse graft. Anti-mouse antibodies cross-reacted with hamster antigens and a hyperacute rejection of a hamster heart graft occurred in a mouse-sensitized rat. Immunofluorescent staining revealed that the antibodies did not bind to hamster heart endothelium, as was expected, but, instead, to graft sarcolemma. DSG treatment prolonged the survival of the first graft by a median of 8 days. Continuous treatment until retransplantation resulted in a prolongation to 30 (20-127) min of the survival of the second graft and no increase in antibody titers against mouse antigens was observed. However, immunofluorescent staining revealed a weak binding of anti-mouse antibodies of the IgM subclass in the rejected mouse heart graft. Additional complement depletion with cobra venom factor in DSG-treated animals resulted in a prolongation of the median graft survival to 48 hr (6-96). No sign or minimal signs of antibody deposition were found in these grafts, but histology revealed massive mononuclear infiltration. In conclusion, xenograft transplantation in a concordant situation results in a shift of antidonor antibody Ig synthesis from IgM to IgG. If daily DSG treatment is administered from the day of transplantation, this reduces the synthesis of antidonor antibodies, and if complement is also depleted, the survival of the second graft is prolonged. The significance of the mononuclear infiltration remains to be established.
authors.affiliation: Department of Transplantation Surgery, University of Uppsala, Sweden.
authors.forename: G
authors.initials: G
authors.lastname: Gannedahl
authors.forename: A
authors.initials: A
authors.lastname: Karlsson-Parra
authors.forename: A
authors.initials: A
authors.lastname: Wallgren
authors.forename: E
authors.initials: E
authors.lastname: Roos-Engstrand
authors.forename: B
authors.initials: B
authors.lastname: Nilsson
authors.forename: T H
authors.initials: TH
authors.lastname: Tötterman
authors.forename: G
authors.initials: G
authors.lastname: Tufveson
mesh_terms: D000818:Animals; D000917:Antibody Formation / Q000187:drug effects / Q000502:physiology*; D000937:Antigen-Antibody Reactions; D000961:Antilymphocyte Serum / Q000032:analysis; D003167:Complement Activation; D003165:Complement System Proteins / Q000032:analysis; D006224:Cricetinae; D004546:Elapid Venoms / Q000494:pharmacology; D005260:Female; D006084:Graft Rejection / Q000276:immunology; D006085:Graft Survival / Q000187:drug effects; D006146:Guanidines / Q000494:pharmacology; D016027:Heart Transplantation / Q000276:immunology*; D007136:Immunoglobulins / Q000032:analysis; D007166:Immunosuppressive Agents / Q000494:pharmacology; D008297:Male; D008647:Mesocricetus; D051379:Mice; D008815:Mice, Inbred Strains; D051381:Rats; D011917:Rats, Inbred Lew; D012086:Reoperation; D013154:Spleen / Q000166:cytology / Q000276:immunology; D014183:Transplantation, Heterologous / Q000276:immunology*
chemical_list: D000961:Antilymphocyte Serum; D004546:Elapid Venoms; D006146:Guanidines; D007136:Immunoglobulins; D007166:Immunosuppressive Agents; C016310:cobra venom factor; D003165:Complement System Proteins; C037258:gusperimus